Life sciences in Ireland: Nurturing talent, innovating excel...
Late last month, pharmaphorum was invited on an IDA Ireland-organised press tour of the life sciences industry in Ireland’s West, permitting an inside peek into the world-class life science
Sorcero genAI conjures plain language from scientific papers
Understanding complex scientific studies is often a challenge for patients as well as healthcare professionals, but one that may become easier thanks to artificial intelli
GSK commits to further support of BioVersys’ TB drug
GSK has expanded a collaboration with BioVersys on a new drug candidate for tuberculosis (TB) and contributed to an extension to the Swiss biotech’s third-round financing.
eyeDNA plans pivotal trial of retinitis pigmentosa therapy
Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regul
Double ApoE4 gene a 'distinct form' of early Alzheimer’s
Having two copies of the ApoE4 gene is not just a risk factor for the development of Alzheimer’s, but is a likely cause of the disease, according to researchers in Spain.<
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Final FDA rule on LDTs creates a paradigm shift for laborato...
WASHINGTON, D.C., April 30, 2024 –The Food and Drug Administration’s (FDA) final rule has reclassified laboratory developed tests (LDTs) as medical devices, according to Avalere.
FT US PHARMA AND BIOTECH SUMMIT
2024 is a pivotal year for the US healthcare sector.
4th Next Generation Gene Therapy Vectors Summit 2024
Accelerate your capsid and payload design with the 4th Next Generation Gene Therapy Vectors Summit (June 12-14, Boston), the industry’s only hub for covering the latest advances and innovations in
2nd ADC Toxicity Summit 2024
Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development
15th World Bispecific Summit 2024
Radically Optimize Bi, Tri & Multispecific Antibodies to Enhance Target Discovery, Mechanistic Diversity & Clinical Translation to Maximize the Therapeutic Index & Enhance Combi